Sharing our research on the global stage at 2021 ASCO Annual Meeting

Sharing our research on the global stage at 2021 ASCO Annual Meeting

7 June 2021

Research from MIA was once again in the spotlight as findings were shared at the virtual ASCO21 - the world’s largest professional oncology meeting.

In addition to the recent story revealing the success of a new immunotherapy trial for melanoma, another 14 abstracts involving our researchers were shared at the conference on the weekend. Here is a snapshot of just a few findings: 

Managing immune-related side effects

Treatment of melanoma with immunotherapy can be lifesaving; however, it can also be complicated by significant side effects as the activated immune system cells may attack healthy cells as well. Most of the side effects occur in the skin, liver, bowel, thyroid gland and lungs, though any organ can be affected.

Immune cells communicate by producing small proteins, called ‘cytokines’, which co-ordinate the body’s response against inflammation. Sometimes this response can go into overdrive, resulting in increased levels of cytokines, making the inflammation worse.

Medical Oncologist Dr Florentia Dimitriou and colleagues identified a cytokine, known as IL-6, which is increased in many inflammatory conditions, including viral infections, like COVID-19, and rheumatoid diseases, such as rheumatoid arthritis.

“We used a specific drug that blocks IL-6, known as tocilizumab, and found the drug reduced the inflammation and lessened the symptoms in these patients,” said Dr Dimitriou. “Based on this observation, the drug we used specifically blocks the activated cytokines and controls the inflammation, without suppressing the immune system.”

Management of Stage III/IV melanoma with immunotherapy after surgery

Immunotherapy after surgery for Stage III melanoma has become the standard treatment approach. Research from Clinical Nurse Consultant Rebecca Johnson and colleagues aimed to understand who is being treated with immunotherapy across Australia, how effective the treatment was, and the variety of treatment options that are implemented if the melanoma recurs.

“Overall, we found the efficacy of treatment was similar to the clinical trials,” said Ms Johnson. “For most patients with melanoma recurrence, there was evidence of disease in distant organs within two years of recurrence. Across the study, these patients were treated with a variety of treatment options.”

Progression on combination immunotherapy

Research from MIA’s Medical Oncologist Dr Ines Silva and her team focussed on patients whose disease progressed after first being treated with combination immunotherapy - drugs that stimulate immune cells to fight cancer. Although around half of these patients are still alive five years after starting treatment, the majority of patients will progress and may require further treatment.

“We looked at how patients’ disease progressed from first-line treatment with a combination of anti-PD1 therapy and ipilimumab, and then determined management strategies for these patients,” said Dr Silva.

“We have shown that in a group of patients, therapy that targets BRAF mutant melanoma, rechallenged with anti-PD1 alone or in combination with ipilimumab and investigational drugs (in clinical trials), showed activity in this setting, and can be considered a treatment option in this context; chemotherapy has no role in these patients.”

Understanding the importance of radiotherapy after surgery in the modern era of immunotherapy

When melanoma spreads from the skin to nearby lymph nodes, the chances of melanoma coming back after it is surgically removed can be quite high for some patients. In this situation, radiotherapy can be given after surgery to the nearby lymph node area to reduce the chance of melanoma returning.

In an era where immunotherapy is now often given to reduce recurrence after surgery, Medical Oncologist Dr Prachi Bhave and colleagues at MIA investigated whether adjuvant radiotherapy is still effective in reducing melanoma recurrence. The study found that radiotherapy significantly reduced the risk of melanoma returning in nearby lymph nodes, and therefore continues to have a role in some patients whose melanoma has returned despite receiving immunotherapy after surgery.

To find out more about the leading research from MIA that was presented at ASCO, you can read their poster presentations here or see abstracts here.

#ASCO21

Prestigious award in pathology for Professor Scolyer
09 Feb 2018

Prestigious award in pathology for Professor Scolyer

Congratulations to Professor Richard Scolyer who was awarded the William O. Russell/Joanne Vandenberge Hill Award of Excellence in Pathology.

A Day in the Life Of... Serigne Lo
09 Feb 2018

A Day in the Life Of... Serigne Lo

A Day in the Life Of... Serigne Lo, Research and BioStatistics Manager at Melanoma Institute Australia

Jay inspires others to help end melanoma and so can you
07 Feb 2018

Jay inspires others to help end melanoma and so can you

Jay was your typical Aussie bloke – a truck driver, husband, dad and mate to many. Then he got melanoma. His cancer diagnosis turned his life upside down.

A dilemma no mother-to-be should face
31 Jan 2018

A dilemma no mother-to-be should face

Clair faced an impossible choice – risk delivering her baby early, or delay potentially life-saving melanoma treatment

Join little Madi and Bettina in the fight against melanoma
25 Jan 2018

Join little Madi and Bettina in the fight against melanoma

Little Madi misses her Dad. But she is determined to honour his memory and support life-saving melanoma research.

Toyota and country music fans invited to tip their hat to help tackle Australia's national cancer – melanoma
19 Jan 2018

Toyota and country music fans invited to tip their hat to help tackle Australia's national cancer – melanoma

Melanoma Institute Australia has teamed up with the Toyota Country Music Festival 2018 in Tamworth!

Sun Protection: Facts and Controversies
18 Jan 2018

Sun Protection: Facts and Controversies

MIA's dermatologist shares her knowledge with GPs on debunking myths and controversies on sunscreen.

Shannan Ponton joins our March for a cure
17 Jan 2018

Shannan Ponton joins our March for a cure

Shannan Ponton thought he was invincible – he wasn’t. But his melanoma battle ended up saving more than his own life. 

Surprising finding in rare form of melanoma get patients closer to personalised medicine
11 Jan 2018

Surprising finding in rare form of melanoma get patients closer to personalised medicine

Researchers have demonstrated that immunotherapy is highly effective in treating a rare form of melanoma – a result that is surprising due to the nature of the tumour.  

Using new technology to prevent melanoma
14 Dec 2017

Using new technology to prevent melanoma

Innovation is helping to prevent melanoma developing in the first place.

Research review of 2017
12 Dec 2017

Research review of 2017

Research from MIA is changing the way melanoma is managed worldwide and improving patient survival. Here are a few of our key highlights from this year.

Translational research funding boost
24 Nov 2017

Translational research funding boost

A prestigious Fellowship has been awarded to fund research that will change the way melanoma treatment is assessed in the future.

New research to guide clinicians to more accurately stage and manage melanoma patients
16 Nov 2017

New research to guide clinicians to more accurately stage and manage melanoma patients

New research from MIA has been published that forms the basis of the updated international guidelines for staging melanoma.

Founding father recognised for outstanding cancer care
15 Nov 2017

Founding father recognised for outstanding cancer care

Professor William McCarthy AM has been awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care.

Melanoma researchers shine at the State's premier cancer awards ceremony
03 Nov 2017

Melanoma researchers shine at the State's premier cancer awards ceremony

Leading researchers from MIA have been acknowledged with three prestigious awards for excellence in melanoma research.

Enhancing melanoma treatment response through gut bacteria
03 Nov 2017

Enhancing melanoma treatment response through gut bacteria

New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.

Melanoma March is just around the corner!
01 Nov 2017

Melanoma March is just around the corner!

2018 will be bigger than ever, and a little bit different.

Comparing melanoma risk in similar populations across different latitudes
20 Oct 2017

Comparing melanoma risk in similar populations across different latitudes

MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.

Congratulations to our Conjoint Medical Directors
19 Oct 2017

Congratulations to our Conjoint Medical Directors

Congratulations to our Conjoint Medical Directors, Professor Georgina Long and Professor Richard Scolyer, who have today been announced as Fellows of the Australian Academy of Health and Medical Sciences.

What causes melanoma in 90% of young Australians?
19 Oct 2017

What causes melanoma in 90% of young Australians?

New research shows potentially deadly UV damage can appear decades earlier than you think.